NextFin News - Morten Foros Krohnstad, the Chair of Lifecare ASA, has fully exercised his warrant holdings to subscribe for 1.6 million new shares, signaling a critical vote of confidence as the medical sensor company navigates a volatile period of capital restructuring. The transaction, announced on March 10, 2026, comes during the exercise period for Warrants Series 1, which were issued following a partially underwritten rights issue completed in January. By executing these warrants at a price of NOK 0.3342 per share, Krohnstad has effectively doubled down on the company’s mission to disrupt the continuous glucose monitoring (CGM) market.
The timing of this insider move is particularly telling. Lifecare’s stock has faced significant downward pressure over the past year, with its market capitalization sliding to approximately NOK 77 million as of early March. Trading on the Oslo Stock Exchange under the ticker LIFE, the shares have recently hovered near the NOK 0.40 mark, representing a staggering decline from the 52-week high of NOK 8.19. For Krohnstad, exercising warrants at NOK 0.3342 is not merely a regulatory formality; it is a calculated bet that the current market valuation fails to reflect the intrinsic potential of Lifecare’s osmotic pressure sensing technology.
Lifecare’s core value proposition rests on its proprietary Sencell technology, which utilizes osmotic pressure to monitor body analytes like glucose. Unlike traditional electrochemical sensors that degrade over time, Lifecare’s approach promises greater longevity and stability, targeting both the human and veterinary markets. However, the path from laboratory breakthrough to commercial scale is notoriously capital-intensive. The January rights issue and the subsequent warrant exercise period, which expires on March 13, 2026, are essential components of the company’s survival and growth strategy. Without the cash infusion from these warrants, the company would struggle to fund the clinical trials necessary for regulatory approval.
The financial mechanics of the warrant exercise reveal a broader narrative of dilution and commitment. Holders who fail to exercise their Series 1 warrants by the Friday deadline will see their instruments lapse without value, facing significant dilution as new shares enter the float. Krohnstad’s decision to exercise his entire allotment—leaving him with no remaining warrants but a significantly bolstered share position—serves as a nudge to other retail and institutional investors. It suggests that the leadership believes the "floor" has been reached, even as the company’s market cap has contracted by over 60% in the last twelve months.
Market reaction to the notification was measured, with the stock showing a slight uptick of 0.21% in recent sessions. Investors are weighing the immediate dilutive impact of the new share issuance against the long-term necessity of the capital. The company expects the share capital increase to be registered with the Norwegian Register of Business Enterprises by March 25, 2026, with new shares hitting accounts the following day. This influx of liquidity is the lifeblood Lifecare needs to transition from a research-heavy entity into a commercial contender in a CGM market currently dominated by giants like Dexcom and Abbott.
The success of Lifecare’s next phase depends on more than just insider participation. While Krohnstad’s 1.6 million share subscription provides a psychological boost, the company must still prove that its osmotic sensing principle can be manufactured at scale and integrated into user-friendly devices. The medical technology sector is littered with firms that possessed superior science but failed the test of commercial viability. For now, the Chair’s move ensures that at least one key stakeholder is prepared to see the clinical journey through to its conclusion, regardless of the current turbulence in the share price.
Explore more exclusive insights at nextfin.ai.
